• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在具有删失指数分布终点的金标准设计中进行非劣效性评估。

The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.

作者信息

Mielke Matthias, Munk A, Schacht A

机构信息

Institut für Mathematische Stochastik, Georg-August-Universität Göttingen, Maschmühlenweg 8-10, D-37073 Göttingen, Germany.

出版信息

Stat Med. 2008 Nov 10;27(25):5093-110. doi: 10.1002/sim.3348.

DOI:10.1002/sim.3348
PMID:18570271
Abstract

The objective of this paper is to develop statistical methodology for non-inferiority hypotheses to censored, exponentially distributed time to event endpoints. Motivated by a recent clinical trial in depression, we consider a gold standard design where a test group is compared with an active reference and with a placebo group. The test problem is formulated in terms of a retention of effect hypothesis. Thus, the proposed Wald-type test procedure assures that the effect of the test group is better than a pre-specified proportion Delta of the treatment effect of the reference group compared with the placebo group. A sample size allocation rule to achieve optimal power is presented, which only depends on the pre-specified Delta and the probabilities for the occurrence of censoring. In addition, a pretest is presented for either the reference or the test group to ensure assay sensitivity in the complete test procedure. The actual type I error and the sample size formula of the proposed tests are explored asymptotically by means of a simulation study showing good small sample characteristics. To illustrate the procedure a randomized, double blind clinical trial in depression is evaluated. An R-package for implementation of the proposed tests and for sample size determination accompanies this paper on the author's web page.

摘要

本文的目的是开发针对删失的指数分布事件发生时间终点的非劣效性假设的统计方法。受最近一项抑郁症临床试验的启发,我们考虑一种金标准设计,即将一个试验组与一个活性对照组以及一个安慰剂组进行比较。检验问题是根据效应保留假设来制定的。因此,所提出的 Wald 型检验程序确保试验组的效应优于对照组与安慰剂组相比治疗效应的预先指定比例 Delta。提出了一种实现最优检验效能的样本量分配规则,该规则仅取决于预先指定的 Delta 和删失发生的概率。此外,还针对对照组或试验组提出了一个预检验,以确保整个检验过程中的分析灵敏度。通过模拟研究渐近地探索了所提出检验的实际一类错误和样本量公式,结果显示出良好的小样本特性。为说明该程序,对一项抑郁症的随机双盲临床试验进行了评估。作者网页上随附了一个用于实施所提出检验和确定样本量的 R 包。

相似文献

1
The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.在具有删失指数分布终点的金标准设计中进行非劣效性评估。
Stat Med. 2008 Nov 10;27(25):5093-110. doi: 10.1002/sim.3348.
2
A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.安慰剂对照和活性药物对照非劣效性试验的两阶段样本量重新计算程序。
Stat Med. 2006 Oct 15;25(19):3396-406. doi: 10.1002/sim.2651.
3
Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.带有主动和安慰剂对照的删失时间事件数据的非劣效性试验的设计和半参数分析。
Stat Med. 2013 Aug 15;32(18):3055-66. doi: 10.1002/sim.5769. Epub 2013 Mar 18.
4
Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.用于在临床试验中检验优效性和非劣效性假设的改良Haybittle-Peto成组序贯设计。
Stat Med. 2006 Apr 15;25(7):1149-67. doi: 10.1002/sim.2357.
5
Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials.活性对照临床试验中用于优效性和非劣效性假设的序贯检验策略。
Stat Med. 2001 Jul 15;20(13):1903-12. doi: 10.1002/sim.820.
6
Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.在包含安慰剂的三臂临床试验中评估新治疗方法的非劣效性。
Stat Med. 2003 Mar 30;22(6):883-99. doi: 10.1002/sim.1450.
7
Multiple-arm superiority and non-inferiority designs with various endpoints.具有多种终点的多臂优效性和非劣效性设计。
Pharm Stat. 2007 Jan-Mar;6(1):43-52. doi: 10.1002/pst.242.
8
Blinded sample size reassessment in non-inferiority and equivalence trials.非劣效性和等效性试验中的盲态样本量重新评估。
Stat Med. 2003 Mar 30;22(6):995-1007. doi: 10.1002/sim.1456.
9
Non-parametric assessment of non-inferiority with censored data.带有删失数据的非劣效性的非参数评估
Stat Med. 2006 Apr 15;25(7):1201-17. doi: 10.1002/sim.2444.
10
Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.在存在不依从和结局缺失的随机试验中,基于比例比评估等效性的样本量确定。
Stat Med. 2008 Jan 15;27(1):47-67. doi: 10.1002/sim.3030.

引用本文的文献

1
Optimization the design of fixed and group sequential three-arm non-inferiority trials with dichotomous endpoints of risk difference and odds ratio.优化具有风险差异和比值比二分终点的固定和序贯三组非劣效性试验的设计。
Contemp Clin Trials Commun. 2024 Oct 18;42:101383. doi: 10.1016/j.conctc.2024.101383. eCollection 2024 Dec.
2
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.在具有事件发生时间终点的随机非劣效性试验设计中,使用比例的非劣效性检验,重点关注低事件率情况。
Clin Trials. 2025 Apr;22(2):131-141. doi: 10.1177/17407745241284786. Epub 2024 Oct 12.
3
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted events.
主动控制随机试验的解读:涉及已避免事件的新分析视角案例。
BMC Med Res Methodol. 2023 Jun 26;23(1):149. doi: 10.1186/s12874-023-01970-0.
4
New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.三臂试验泊松分布结局非劣效性检验的新方法。
Biostatistics. 2022 Jan 13;23(1):136-156. doi: 10.1093/biostatistics/kxaa014.
5
NONPARAMETRIC TESTING FOR MULTIPLE SURVIVAL FUNCTIONS WITH NON-INFERIORITY MARGINS.具有非劣效性界值的多个生存函数的非参数检验
Ann Stat. 2019 Feb;47(1):205-232. doi: 10.1214/18-AOS1686. Epub 2018 Nov 30.
6
Effects of three home-based exercise programmes regarding falls, quality of life and exercise-adherence in older adults at risk of falling: protocol for a randomized controlled trial.三种基于家庭的运动方案对老年跌倒高风险人群跌倒、生活质量和运动依从性的影响:一项随机对照试验的方案。
BMC Geriatr. 2019 Jan 14;19(1):13. doi: 10.1186/s12877-018-1021-y.
7
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.避免感染率:一种评估实验性 HIV 暴露前预防药物效果的新指标。
Lancet HIV. 2018 Jun;5(6):e329-e334. doi: 10.1016/S2352-3018(18)30045-6.
8
Group-sequential three-arm noninferiority clinical trial designs.成组序贯三臂非劣效性临床试验设计
J Biopharm Stat. 2017;27(1):1-24. doi: 10.1080/10543406.2016.1148710. Epub 2016 Feb 18.